Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4022/jafib.752 http://scihub22266oqcxt.onion/10.4022/jafib.752 C5153170!5153170!28496824     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Atr+Fibrillation 2013 ; 5 (6): ä Nephropedia Template TP {{tp|p=28496824|t=2013. Dronedarone: Where Does it Fit in the AF Therapeutic Armamentarium?|pdf=|usr=}}{{28496824}} gab.com Text Dronedarone: Where Does it Fit in the AF Therapeutic Armamentarium JO: J Atr Fibrillation http://www.kidney.de/pget.php?&tw=1&pmid=28496824 #FOAvip Dronedarone is a derivative of amiodarone with similar mechanisms of action (blocking calcium, potassium and sodium channels in addition to having anti-adrenergic effects). Compared to amiodarone it has fewer drug interactions (though it can interact with all current anticoagulants), more limited risk of organ toxicity, a much shorter half-life with no need for a loading regimen, but lower efficacy. Dronedarone is approved for the treatment of atrial fibrillation; has had limited studies for other arrhythmias; and has no adverse drug-ICD interactions reported. Clinical trials have resulted in only one dosing regimen (400 mg bid, to be taken with food) and have demonstrated both rate and rhythm effects in atrial fibrillation (AF). Dronedarone slows the ventricular response, can prolong the time to/reduce recurrences of/ reduce progression of AF, and reduce the incidence of hospitalization in AF patients with risk-prone markers. However, trials have also revealed an increased risk of mortality and other adverse cardiovascular outcomes from dronedarone when given to patients in heart failure. The details of these trials, additional pharmacokinetic and pharmacodynamic information, and recommendations concerning the use of dronedarone are provided in the full manuscript that follows. Twit Text FOAVip Dronedarone: Where Does it Fit in the AF Therapeutic Armamentarium ????J Atr Fibrillation http://www.kidney.de/pget.php?&tw=1&pmid=28496824 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28496824 #FOAvip English Wikipedia <ref>{{Cite pmid|28496824}}</ref> Dronedarone: Where Does it Fit in the AF Therapeutic Armamentarium? #MMPMID28496824 Reiffel JA J Atr Fibrillation 2013[Apr]; 5 (6): ä PMID28496824show ga Dronedarone is a derivative of amiodarone with similar mechanisms of action (blocking calcium, potassium and sodium channels in addition to having anti-adrenergic effects). Compared to amiodarone it has fewer drug interactions (though it can interact with all current anticoagulants), more limited risk of organ toxicity, a much shorter half-life with no need for a loading regimen, but lower efficacy. Dronedarone is approved for the treatment of atrial fibrillation; has had limited studies for other arrhythmias; and has no adverse drug-ICD interactions reported. Clinical trials have resulted in only one dosing regimen (400 mg bid, to be taken with food) and have demonstrated both rate and rhythm effects in atrial fibrillation (AF). Dronedarone slows the ventricular response, can prolong the time to/reduce recurrences of/ reduce progression of AF, and reduce the incidence of hospitalization in AF patients with risk-prone markers. However, trials have also revealed an increased risk of mortality and other adverse cardiovascular outcomes from dronedarone when given to patients in heart failure. The details of these trials, additional pharmacokinetic and pharmacodynamic information, and recommendations concerning the use of dronedarone are provided in the full manuscript that follows. äDronedarone: Where Does it Fit in the AF Therapeutic Armamentarium?(epmc).pdf DeepDyve Pubget Overpricing